Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare CVE:AEXNASDAQ:BLUNYSE:PED On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEXAEX GoldC$0.62-1.6%C$0.62C$0.44▼C$0.82C$109.80MN/A28,496 shs8,500 shsBLUBELLUS Health$14.74$14.62$6.38▼$14.76$1.87B0.193.08 million shs3.45 million shsPEDPEDEVCO$0.63-8.6%$0.61$0.47▼$1.10$57.18M0.3101,255 shs193,825 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEXAEX Gold0.00%0.00%0.00%0.00%0.00%BLUBELLUS Health0.00%0.00%0.00%0.00%0.00%PEDPEDEVCO0.00%+18.00%+11.81%-16.76%-33.24%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAEXAEX GoldN/AN/AN/AN/AN/AN/AN/AN/ABLUBELLUS HealthN/AN/AN/AN/AN/AN/AN/AN/APEDPEDEVCO3.1591 of 5 stars3.50.00.00.00.61.73.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEXAEX Gold 0.00N/AN/AN/ABLUBELLUS Health 0.00N/AN/AN/APEDPEDEVCO 3.00Buy$1.63159.58% UpsideCurrent Analyst Ratings BreakdownLatest BLU, AEX, CTP, and PED Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/2/2025PEDPEDEVCOD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$1.50 ➝ $1.503/13/2025PEDPEDEVCOD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$1.50 ➝ $1.50(Data available from 5/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEXAEX GoldN/AN/AC$0.13 per share4.59C$0.21 per shareN/ABLUBELLUS Health$15K124,613.93N/AN/A$3.09 per share4.77PEDPEDEVCO$39.55M1.45$0.10 per share6.21$1.13 per share0.55Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEXAEX GoldN/A-C$0.14N/A∞N/AN/AN/AN/AN/ABLUBELLUS Health-$76.08M-$0.72N/AN/AN/A-578,586.63%-24.27%-23.14%N/APEDPEDEVCO$260K$0.1931.328.94N/A6.57%1.58%1.39%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEXAEX GoldN/AN/AN/AN/AN/ABLUBELLUS HealthN/AN/AN/AN/AN/APEDPEDEVCON/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEXAEX Gold2.0919.9019.77BLUBELLUS HealthN/A33.4233.42PEDPEDEVCON/A2.102.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEXAEX GoldN/ABLUBELLUS Health90.37%PEDPEDEVCO3.26%Insider OwnershipCompanyInsider OwnershipAEXAEX GoldN/ABLUBELLUS Health24.17%PEDPEDEVCO70.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEXAEX GoldN/A177.10 millionN/ANot OptionableBLUBELLUS Health74126.81 million96.16 millionNot OptionablePEDPEDEVCO1091.34 million26.31 millionNot OptionableBLU, AEX, CTP, and PED HeadlinesRecent News About These CompaniesPEDEVCO (NYSE:PED) Coverage Initiated at StockNews.comMay 16 at 3:19 AM | marketbeat.comPedevco Corp. (PED) Reports Break-Even Earnings for Q1May 15 at 7:16 PM | zacks.comPEDEVCO Corp.: PEDEVCO Announces Q1 2025 Financial Results and Operations UpdateMay 15 at 5:19 PM | finanznachrichten.dePEDEVCO Announces Q1 2025 Financial Results and Operations UpdateMay 15 at 4:31 PM | accessnewswire.comShould Value Investors Buy Pedevco (PED) Stock?May 7, 2025 | zacks.comStockNews.com Begins Coverage on PEDEVCO (NYSE:PED)April 21, 2025 | marketbeat.comPEDEVCO Announces 2024 Financial ResultsMarch 31, 2025 | accessnewswire.comPEDEVCO Provides Permian Basin Operational UpdateMarch 11, 2025 | accessnewswire.comPEDEVCO to Participate in the 37th Annual ROTH ConferenceMarch 10, 2025 | accessnewswire.comRoth MKM Reaffirms Their Buy Rating on Pedevco (PED)March 6, 2025 | markets.businessinsider.comPEDEVCO Corp.: PEDEVCO Announces Entry into Joint Development Agreement with Large Private Equity-Backed D-J Basin E&P CompanyMarch 3, 2025 | finanznachrichten.dePedevco enters joint development agreement with D-J Basin E&P companyMarch 3, 2025 | markets.businessinsider.comPEDEVCO Announces Entry into Joint Development Agreement with Large Private Equity-Backed D-J Basin E&P CompanyMarch 3, 2025 | accessnewswire.com3 Oil & Gas Equipment Stocks Set to Gain From a Promising IndustryFebruary 27, 2025 | zacks.comPEDEVCO Corp. (NYSE:PED) CAO Sells $19,550.00 in StockJanuary 28, 2025 | insidertrades.comPedevco corp officer sells shares worth $69,218January 27, 2025 | msn.comPedevco Corp CEO John Douglas Schick sells $141,182 in stockJanuary 27, 2025 | msn.comPEDEVCO Announces Appointment of New Chief Executive Officer, New Chief Commercial Officer, and Board of Director ChangesDecember 11, 2024 | accesswire.comPEDEVCO Corp.: PEDEVCO Announces Q3 2024 Financial Results and Operations UpdateNovember 15, 2024 | finanznachrichten.dePedevco Corp. (PED) Q3 Earnings Match EstimatesNovember 14, 2024 | zacks.comPEDEVCO Announces Q3 2024 Financial Results and Operations UpdateNovember 14, 2024 | accesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Why D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumAST SpaceMobile: 5 Reasons to Buy This Tiny Trailblazer StockBy Jea Yu | April 21, 2025View AST SpaceMobile: 5 Reasons to Buy This Tiny Trailblazer Stock3 Alternative Asset Managers Are Raising Dividends by 5% to 25%By Leo Miller | May 13, 2025View 3 Alternative Asset Managers Are Raising Dividends by 5% to 25%Hidden Gems: 3 Quiet Stocks With Loud PotentialBy Nathan Reiff | April 23, 2025View Hidden Gems: 3 Quiet Stocks With Loud PotentialBLU, AEX, CTP, and PED Company DescriptionsAEX Gold CVE:AEXC$0.62 -0.01 (-1.59%) As of 07/11/2022AEX Gold Inc. engages in the acquisition, exploration, and development of mineral properties in Greenland. It holds interests in licenses covering an area of 7,615.85 square kilometers located in South Greenland. The company was formerly known as Alopex Gold Inc. and changed its name to AEX Gold Inc. in June 2018. AEX Gold Inc. was incorporated in 2017 and is headquartered in Toronto, Canada.BELLUS Health NASDAQ:BLUBELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. BELLUS Health Inc. was incorporated in 1993 and is based in Laval, Canada. As of June 28, 2023, BELLUS Health Inc. operates as a subsidiary of GSK plc.PEDEVCO NYSE:PED$0.63 -0.06 (-8.60%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$0.64 +0.02 (+3.04%) As of 05/16/2025 06:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PEDEVCO Corp., an oil and gas company, focuses on the acquisition, development, and production of oil and natural gas assets in the United States. It holds interests in the Permian Basin asset covering an area of approximately 22,721 net acres located in New Mexico; and D-J Basin asset covering an area of approximately 19,214 net acres located in Wyoming. The company is headquartered in Houston, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/12 - 05/16 Retail Investors Are Betting Big on Rocket Lab—Should You Too? Meta's 5 Key Pillars for AI Growth—Zuckerberg's Bold Vision Taiwan Semiconductor Stock Is The Gift That Keeps on Giving GE Aerospace: Qatar Deal Fuels Multi-Billion Dollar Growth Engine Alibaba's Earnings Just Changed Everything for the Stock Plug Power: Is Q1 Noise An Opportunity for Accumulation? Cisco Stock Eyes New Highs in 2025 on AI, Earnings, Upgrades Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
